Conducting Clinical Trials in Developing Countries has now become a necessity as the Clinical Research world in North America and Europe are saturated. Furthermore the studies diseases are prevalent in the developing countries, there is a therapeutic need for the patient population, and there are high enrolment rates. However these countries often come with a few concerns, one of the major ones being the ethical reviews and concerns for the conduct of research. Before moving a clinical trial to a developing country, it is important to be reassured on all ethical quality and integrity of data before choosing the site.
Mauritius currently has a well-established legal framework with the presence of a Regulatory Body, Ethical Committee and Pharmacovigilance Committee who are the pillars of controlling the conduct of Clinical Trials in the country as well as ensuring that the ethical and safety standards for all patients are respected during the conduct of the trials.
Mauritius is the 3rd country in the world in terms of diabetes prevalence with 24.3% in adult population. The high prevalence and the poor control of this disease is due to the fact that there is a poor metabolic control of the patients' glucose level as well as an unhealthy diet and lack of exercise since a young age which contributes to 33% of the adult population being overweight or obese. In Mauritius there is 1 on 2 people who are diabetic or prediabetic. This double burden of diabetes will soon contribute to being a significant threat in terms of the future social and economic burden of heart disease and diabetes complications for Mauritius which will have a direct impact on the countries medical costs and workforce over the years to come.
CIDP participated in the 3rd International Conference on Advanced Clinical Research and Clinical Trials in Dublin to deliver a presentation on conducting a clinical trial in Mauritius and the rise of diabetes in this country. It has been a huge success as diabetes is a concern for a lot of pharmaceutical companies.
Dublin, Ireland, the 20-21 september 2017